We are live on ! Find out more
AA

AlphaMark Advisors Portfolio holdings

AUM $231M
1-Year Est. Return 19.98%
This Fund
S&P 500
This Quarter Est. Return
+6.81%
1 Year Est. Return
+19.98%
3 Year Est. Return
+26.38%
5 Year Est. Return
+72.27%
10 Year Est. Return
+180.76%
AUM
$239M
AUM Growth
+$8.32M
Cap. Flow
-$5.16M
Cap. Flow %
-2.16%
Top 10 Hldgs %
35.11%
Holding
546
New
36
Increased
93
Reduced
108
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$3.15M
2
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
3
DLTR icon
Dollar Tree
DLTR
+$1.94M
4
VTV icon
Vanguard Morningstar Value ETF
VTV
+$857K
5
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$833K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$4.4M
2
EOG icon
EOG Resources
EOG
+$2.91M
3
UTHR icon
United Therapeutics
UTHR
+$2.5M
4
ZBRA icon
Zebra Technologies
ZBRA
+$1.98M
5
PVH icon
PVH
PVH
+$1.43M

Sector Composition

Rank Sector Weight
1 Financials 10.55%
2 Consumer Staples 7.28%
3 Technology 6.91%
4 Consumer Discretionary 6.75%
5 Industrials 6.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VWO icon
451
Vanguard FTSE Emerging Markets ETF
VWO
$121B
$2K ﹤0.01%
40
-2,100
-98% -$89K
WAT icon
452
Waters Corp
WAT
$37B
$2K ﹤0.01%
10
– –
XLB icon
453
State Street Materials Select Sector SPDR ETF
XLB
$8.5B
$2K ﹤0.01%
74
– –
AMJ
454
DELISTED
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
$2K ﹤0.01%
70
-10
-13% -$215
CDK
455
DELISTED
CDK Global, Inc.
CDK
$2K ﹤0.01%
36
– –
GSKY
456
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
$2K ﹤0.01%
190
– –
BXRX
457
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
0
– –
MXIM
458
DELISTED
Maxim Integrated Products
MXIM
$2K ﹤0.01%
+25
New +$1.46K
CHK
459
DELISTED
Chesapeake Energy Corporation
CHK
$2K ﹤0.01%
10
– –
ACA icon
460
Arcosa
ACA
$7.13B
$1K ﹤0.01%
33
– –
CHE icon
461
Chemed
CHE
$7.07B
$1K ﹤0.01%
3
– –
GLL icon
462
ProShares UltraShort Gold
GLL
$127M
$1K ﹤0.01%
6
– –
HTGC icon
463
Hercules Capital
HTGC
$3.07B
$1K ﹤0.01%
90
– –
LRN icon
464
Stride
LRN
$3.41B
$1K ﹤0.01%
34
– –
NKE icon
465
Nike
NKE
$61.9B
$1K ﹤0.01%
6
– –
PFBC icon
466
Preferred Bank
PFBC
$1.24B
$1K ﹤0.01%
17
– –
SSTK icon
467
Shutterstock
SSTK
$198M
$1K ﹤0.01%
12
– –
USO icon
468
United States Oil Fund
USO
$2.15B
$1K ﹤0.01%
9
– –
VOD icon
469
Vodafone
VOD
$36.3B
$1K ﹤0.01%
57
-400
-88% -$7.97K
SWN
470
DELISTED
Southwestern Energy Company
SWN
$1K ﹤0.01%
409
– –
PRSP
471
DELISTED
Perspecta Inc. Common Stock
PRSP
$1K ﹤0.01%
20
– –
APHA
472
DELISTED
Aphria Inc. Common Shares
APHA
$1K ﹤0.01%
280
– –
NBL
473
DELISTED
Noble Energy, Inc.
NBL
$1K ﹤0.01%
28
– –
VAL
474
DELISTED
Valaris plc Class A Ordinary Share
VAL
$1K ﹤0.01%
125
-1,747
-93% -$8.51K
CTST
475
DELISTED
CannTrust Holdings Inc. Common Share
CTST
$1K ﹤0.01%
1,015
– –
17 18
19
20 21

Similar funds

AJ
Ashburton (Jersey) St Helier, Jersey $227M AUM
MWS
Maxwell Wealth Strategies Pleasanton, California $245M AUM 23.39% 1-Year Est. Return
LHR
Lunate Holding RSC Al Maryah Island, Abu Dhabi, United Arab Emirates $211M AUM
HPFG
Hart & Patterson Financial Group Amherst, Massachusetts $206M AUM 7.82% 1-Year Est. Return
GWM
Gray Wealth Management Bangor, Maine $264M AUM 19.5% 1-Year Est. Return
KC
Kades & Cheifetz Berwyn, Pennsylvania $195M AUM 11.87% 1-Year Est. Return
SL
SIB LLC New York, New York $190M AUM 9.27% 1-Year Est. Return
CSWM
Cassady Schiller Wealth Management Cincinnati, Ohio $273M AUM 17.91% 1-Year Est. Return

AlphaMark Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, AlphaMark Advisors held 546 positions worth $239M, up 3.6% from $231M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

AlphaMark Advisors's Q4 2019 filing shows 36 new, 93 increased, 108 reduced and 33 closed positions. Its largest new stake was Alexion Pharmaceuticals: 29,481 shares worth $3.19M. The largest sale was Celgene Corp, an estimated $4.4M.

By sector, the portfolio is most concentrated in Financials at 11% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Technology.

  • AlphaMark Advisors's largest Q4 2019 buy was Alexion Pharmaceuticals: 29,481 shares worth $3.19M.
  • AlphaMark Advisors added most to Bristol-Myers Squibb in Q4 2019, an estimated $2.48M increase.
  • AlphaMark Advisors's biggest Q4 2019 reduction was EOG Resources, cutting an estimated $2.91M.
  • AlphaMark Advisors fully exited Celgene Corp in Q4 2019, selling an estimated $4.4M.
  • AlphaMark Advisors's ten largest holdings make up 35% of its $239M portfolio in Q4 2019.
  • AlphaMark Advisors opened 36 new positions and closed 33 in Q4 2019.
  • AlphaMark Advisors's portfolio value rose 3.6% quarter-over-quarter to $239M.

Based on AlphaMark Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.